-
公开(公告)号：US09107821B2
公开(公告)日：2015-08-18
申请号：US13592228
申请日：2012-08-22
Applicant: Kumaresh Soppimath , Satish Pejaver , Kanaiyalal R. Patel , Lakkaraju Dasaradhi , Rama Sodum , Hari Desu , Navneet Puri
Inventor： Kumaresh Soppimath , Satish Pejaver , Kanaiyalal R. Patel , Lakkaraju Dasaradhi , Rama Sodum , Hari Desu , Navneet Puri
CPC classification number: A61K9/08 , A61K9/0019 , A61K9/19 , A61K31/4965 , A61K31/69 , A61K47/10 , C07B63/04
Abstract: Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.
Abstract translation: 硼替佐米的多剂量制剂被提出，其中硼替佐米具有显着改善的稳定性。 特别优选的制剂包括硼替佐米是适合注射的液体形式的制剂，其中溶剂体系主要包含丙二醇。 在其他优选方面，硼替佐米作为具有异双功能路易斯碱的路易斯供体 - 受体复合物存在。
-
公开(公告)号：US20140080880A1
公开(公告)日：2014-03-20
申请号：US14030201
申请日：2013-09-18
Applicant: InnoPharma, Inc.
Inventor： Udaya Toti , Kumaresh Soppimath , Rekha Nayak , Satish Pejaver , Navneet Puri
IPC: A61K31/4184 , A61K9/19
CPC classification number: A61K31/4184 , A61K9/0019 , A61K9/19 , A61K47/26
Abstract: A lyophilized bendamustine composition consisting of bendamustine hydrochloride, an aqueous solvent, and optionally an excipient, and a method of preparation thereof for treating a condition in a subject are provided. The aqueous solvent includes, for example, water, an acid, a base, or a salt, etc. The excipient includes at least one cryoprotectant, for example, sucrose, trehalose, mannitol, etc. A pre-lyophilization bendamustine composition is lyophilized, for example, by freezing, primary drying, annealing, secondary drying, condensed cooling and evacuation at preset temperatures to obtain the lyophilized bendamustine composition as a cake, a powder, or a solid concentrate. The lyophilized bendamustine composition is free of a non-aqueous solvent. Reconstitution is performed by mixing the lyophilized bendamustine composition with an aqueous solvent for about 30 seconds to 300 seconds. The reconstituted bendamustine product containing about 0.2 wt % to about 2.5 wt % by weight of impurities is administered to the subject in need thereof.
Abstract translation: 提供了由盐酸苯达莫司汀，水性溶剂和任选的赋形剂组成的冻干的苯达莫司汀组合物及其用于治疗受试者的病症的制备方法。 水性溶剂包括例如水，酸，碱或盐等。赋形剂包括至少一种冷冻保护剂，例如蔗糖，海藻糖，甘露醇等。将冻干前冻干抑制药组合物冻干， 例如通过冷冻，初次干燥，退火，二次干燥，冷凝冷却和在预设温度下排空，以获得作为饼状物，粉末或固体浓缩物的冻干的苯达莫司汀组合物。 冻干的苯达莫司汀组合物不含非水溶剂。 通过将冻干的苯达莫司汀组合物与水性溶剂混合约30秒至300秒进行重构。 将含有约0.2重量％至约2.5重量％杂质的复原苯达莫司汀产品施用于有需要的受试者。
-
公开(公告)号：US20130317016A1
公开(公告)日：2013-11-28
申请号：US13901978
申请日：2013-05-24
Applicant: Innopharma, Inc.
Inventor： Tushar Hingorani , Kumaresh Soppimath , Satish Pejaver , Navneet Puri
IPC: A61K31/5377
CPC classification number: A61K31/5377 , A61K9/0019 , A61K9/08 , A61K47/10 , A61K47/18 , A61K47/24 , A61K47/26 , A61K47/44
Abstract: An aqueous stable and ready-to-use formulation of aprepitant is prepared. Especially preferred formulations comprise a synergistic combination of a co-solvent and a surfactant and may further include a secondary co-solvent. Among other advantages of contemplated formulations, aprepitant is dissolved at high concentrations and remains dissolved and stable, even over prolonged periods of time.
Abstract translation: 制备一种水性稳定且即用型的阿瑞匹坦制剂。 特别优选的制剂包括助溶剂和表面活性剂的协同组合，并且还可以包括仲辅助溶剂。 除了预期制剂的其它优点之外，阿瑞匹坦剂以高浓度溶解并保持溶解和稳定，即使在长时间内也是如此。
-
公开(公告)号：US20120322763A1
公开(公告)日：2012-12-20
申请号：US13592235
申请日：2012-08-22
Applicant: Kumaresh Soppimath , Satish Pejaver , Kanaiyalal R. Patel , Lakkaraju Dasaradhi , Rama Sodum , Hari Desu , Navneet Puri
Inventor： Kumaresh Soppimath , Satish Pejaver , Kanaiyalal R. Patel , Lakkaraju Dasaradhi , Rama Sodum , Hari Desu , Navneet Puri
IPC: A61K31/69
CPC classification number: A61K9/08 , A61K9/0019 , A61K9/19 , A61K31/4965 , A61K31/69 , A61K47/10 , C07B63/04
Abstract: Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.
-
公开(公告)号：US09180093B2
公开(公告)日：2015-11-10
申请号：US13592235
申请日：2012-08-22
Applicant: Kumaresh Soppimath , Satish Pejaver , Kanaiyalal R. Patel , Lakkaraju Dasaradhi , Rama Sodum , Hari Desu , Navneet Puri
Inventor： Kumaresh Soppimath , Satish Pejaver , Kanaiyalal R. Patel , Lakkaraju Dasaradhi , Rama Sodum , Hari Desu , Navneet Puri
CPC classification number: A61K9/08 , A61K9/0019 , A61K9/19 , A61K31/4965 , A61K31/69 , A61K47/10 , C07B63/04
Abstract: Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.
-
Patent Agency Ranking
公开(公告)号：US20140073583A1
公开(公告)日：2014-03-13
申请号：US14023247
申请日：2013-09-10
Applicant: InnoPharma, Inc.
Inventor： Ketan Hippalgaonkar , Kumaresh Soppinath , Satish Pejaver , Navneet Puri
IPC: A61K38/07
Abstract: The invention relates to pharmaceutical compositions that provide improved solubility and stability for peptide epoxy ketones. More specifically, the invention relates to pharmaceutical compositions comprising the peptide epoxy ketone proteasome inhibitor carfilzomib.
Abstract translation: 本发明涉及为肽环氧酮提供改善的溶解度和稳定性的药物组合物。 更具体地，本发明涉及包含肽环氧酮蛋白酶体抑制剂carfilzomib的药物组合物。
-
公开(公告)号：US10251891B2
公开(公告)日：2019-04-09
申请号：US15333529
申请日：2016-10-25
Applicant: InnoPharma, Inc.
Inventor： Udaya Toti , Shyamprasad Mukundan , Sasank Chaitanya Kunadharaju , Tushar Hingorani , Kumaresh Soppimath , Satish Pejaver , Navneet Puri
Abstract: A liquid pharmaceutical compositions comprising Aprepitant is preferably prepared as an oral suspension dosage form for the prevention and control of acute and delayed chemotherapy induced nausea and vomiting, and/or for prevention of postoperative nausea and vomiting.
-
公开(公告)号：US09061037B2
公开(公告)日：2015-06-23
申请号：US13051102
申请日：2011-03-18
Applicant: Kumaresh Soppimath , Satish Pejaver , Kanaiyalal R. Patel , Lakkaraju Dasaradhi , Rama Sodum , Hari Desu , Navneet Puri
Inventor： Kumaresh Soppimath , Satish Pejaver , Kanaiyalal R. Patel , Lakkaraju Dasaradhi , Rama Sodum , Hari Desu , Navneet Puri
CPC classification number: A61K31/69 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K31/4965 , A61K47/10
Abstract: Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.
-
9.发明申请公开(公告)号：US20220023238A1
公开(公告)日：2022-01-27
申请号：US17496276
申请日：2021-10-07
Applicant: InnoPharma, Inc.
Inventor： Tushar Hingorani , Tushar Malkan , Sasank Kunadharaju , Satish Pejaver
Abstract: A process for minimizing formation of a highest degradation product during moist heat sterilization of a drug solution of an oxidation susceptible active pharmaceutical ingredient (API) is provided, wherein the water is not deoxygenated and a nitrogen blanket is not used during formulation, or the formulation is stored in ambient conditions in the polymer bag and autoclaved. The highest degradation product in the parenteral drug product is less than 0.1% by weight of a labeled amount of the oxidation susceptible API in the parenteral drug product.
-
公开(公告)号：US20130210878A1
公开(公告)日：2013-08-15
申请号：US13749443
申请日：2013-01-24
Applicant: Innopharma, Inc.
Inventor： Kumaresh Soppimath , Udaya Toti , Satish Pejaver , Navneet Puri
IPC: A61K47/02
CPC classification number: A61K47/02 , A61K9/0019 , A61K31/4184 , A61K47/10
Abstract: Aqueous Bendamustine formulations with improved stability are disclosed. Especially preferred formulations are low-dose ready-to-use liquid formulations in which Bendamustine is in a non-aqueous vehicle in combination with an aqueous phase that contains significant quantities of chloride.
Abstract translation: 公开了具有改善的稳定性的苯达莫司汀配方。 特别优选的制剂是低剂量即用型液体制剂，其中苯达莫司汀与含有大量氯化物的水相组合在非水载体中。
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.036 seconds)
